The estimated Net Worth of Axel Bolte is at least $915 mil dollars as of 11 May 2023. Mr Bolte owns over 14,588 units of Inozyme Pharma stock worth over $115,078 and over the last 11 years he sold INZY stock worth over $28,980. In addition, he makes $771,398 as Co-Founder, Pres, e CEO & Director at Inozyme Pharma.
Mr has made over 7 trades of the Inozyme Pharma stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 14,588 units of INZY stock worth $76,003 on 11 May 2023.
The largest trade he's ever made was buying 67,750 units of Inozyme Pharma stock on 19 April 2022 worth over $249,998. On average, Mr trades about 7,755 units every 150 days since 2013. As of 11 May 2023 he still owns at least 22,088 units of Inozyme Pharma stock.
You can see the complete history of Mr Bolte stock trades at the bottom of the page.
Axel Bolte M.B.A., M.Sc. is the Co-Founder, Pres, CEO & Director at Inozyme Pharma.
As the Co-Founder, Pres, e CEO & Director of Inozyme Pharma, the total compensation of Mr Sc at Inozyme Pharma is $771,398. There are no executives at Inozyme Pharma getting paid more.
Mr Sc is 49, he's been the Co-Founder, Pres, e CEO & Director of Inozyme Pharma since . There are 4 older and 1 younger executives at Inozyme Pharma. The oldest executive at Inozyme Pharma, Inc. is Dr. Pedro Huertas, 64, who is the Sr. VP & Chief Medical Officer.
Axel's mailing address filed with the SEC is C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON, MA, 02210.
Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma executives and other stock owners filed with the SEC include: